150 related articles for article (PubMed ID: 38325328)
21. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
22. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
23. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
[TBL] [Abstract][Full Text] [Related]
24. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
25. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma.
Whitlock RS; Loo C; Patel K; Bista R; Goss JA; Heczey A; Khan O; Lopez-Terrada D; Masand P; Nguyen H; Mahvash A; Vasudevan SA; Kukreja K
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1181-e1185. PubMed ID: 33769387
[TBL] [Abstract][Full Text] [Related]
26. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
27. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
28. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
[TBL] [Abstract][Full Text] [Related]
29. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.
Floridi C; Pesapane F; Angileri SA; De Palma D; Fontana F; Caspani F; Barile A; Del Sole A; Masciocchi C; Lucignani G; Carrafiello G
Med Oncol; 2017 Sep; 34(10):174. PubMed ID: 28875374
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
[TBL] [Abstract][Full Text] [Related]
31. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract][Full Text] [Related]
32. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery.
Meerun MA; Allimant C; Rivière B; Herrero A; Panaro F; Assenat E; Cassinotto C; Mariano-Goulart D; Guiu B
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):351-365. PubMed ID: 37351147
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection.
Kim J; Kim JY; Lee JH; Sinn DH; Hur MH; Hong JH; Park MK; Cho HJ; Choi NR; Lee YB; Cho EJ; Yu SJ; Kim YJ; Paeng JC; Kim HC; Yi NJ; Lee KW; Suh KS; Hyun D; Kim JM; Yoon JH
J Nucl Med; 2022 Aug; 63(8):1215-1222. PubMed ID: 34887340
[TBL] [Abstract][Full Text] [Related]
34. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
35. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
36. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
[TBL] [Abstract][Full Text] [Related]
37. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma.
Qadan M; Fong ZV; Delman AM; Gabr A; Salem R; Shah SA
J Gastrointest Surg; 2021 Oct; 25(10):2690-2699. PubMed ID: 34345997
[TBL] [Abstract][Full Text] [Related]
38. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
[TBL] [Abstract][Full Text] [Related]
39. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
Vouche M; Salem R; Lewandowski RJ; Miller FH
Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
[TBL] [Abstract][Full Text] [Related]
40. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]